Recent Investment Analysts’ Ratings Updates for Hyperion DeFi (HYPD)

Several brokerages have updated their recommendations and price targets on shares of Hyperion DeFi (NASDAQ: HYPD) in the last few weeks:

• 9/10/2026 – Hyperion DeFi had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $11.20 price target on the stock, up from $7.10.
• 9/10/2026 – Hyperion DeFi was upgraded by Zacks Research from “strong sell” to “hold”.
• 9/8/2026 – Hyperion DeFi had its price target raised by Chardan Capital from $7.30 to $8.45. They now have a “buy” rating on the stock.
• 9/1/2026 – Hyperion DeFi was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 8/18/2026 – Hyperion DeFi was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 8/13/2026 – Hyperion DeFi had its price target raised by Cantor Fitzgerald from $6.60 to $7.10. They now have an “overweight” rating on the stock.
• 8/12/2026 – Hyperion DeFi was downgraded by Zacks Research from “hold” to “strong sell”.
• 8/11/2026 – Hyperion DeFi had its “buy” rating reaffirmed by Chardan Capital. They now have a $7.30 price target on the stock.

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.